EUROPEAN
COMMISSION

Brussels, XXX
SANTE/10388/2020 ANNEX
(POOL/E4/2020/10388/10388-EN
ANNEX.docx)
[…](2020) XXX draft

ANNEX

ANNEX

to the

COMMISSION IMPLEMENTING REGULATION (EU) …/...

approving carbendazim as an existing active substance for use in biocidal products of product-types 7 and 10

ANNEX

Common Name	IUPAC Name Identification Numbers	Minimum degree of purity of the active substance[1]	Date of approval	Expiry date of approval	Product type	Specific conditions
Carbendazim	IUPAC Name: Methyl-benzimidazol-2-ylcarbamate EC No: 234-234-0 CAS No: 10605-21-7	99,0% w/w	1 February 2022	31 January 2025	7	Carbendazim is considered a candidate for substitution in accordance with points (a) and (d) of Article 10(1) of Regulation (EU) No 528/2012. The authorisations of biocidal products are subject to the following conditions: 1) The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance. In addition, pursuant to point 10 of Annex VI to Regulation (EU) No 528/2012, the product assessment shall include an evaluation as to whether the conditions of Article 5(2) of Regulation (EU) No 528/2012 can be satisfied. 2) Products shall only be authorised for use in Member States where at least one of the conditions laid down in Article 5(2) of Regulation (EU) No 528/2012 is met. 3) In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to surface water, sediment, soil and groundwater for products used in paints which are intended to be used outdoors. The placing on the market of treated articles is subject to the condition that the person responsible for the placing on the market of a treated article treated with or incorporating carbendazim shall ensure that the label of that treated article provides the information listed in the second subparagraph of

[1] The purity indicated in this column was the minimum degree of purity of the active substance evaluated. The active substance in the product placed on the market can be of equal or different purity if it has been proven to be technically equivalent to the evaluated active substance.

						Article 58(3) of Regulation (EU) No 528/2012.
					10	Carbendazim is considered a candidate for substitution in accordance with points (a) and (d) of Article 10(1) of Regulation (EU) No 528/2012. The authorisations of biocidal products are subject to the following conditions: 1) The product assessment shall pay particular attention to the exposures, the risks and the efficacy linked to any uses covered by an application for authorisation, but not addressed in the Union level risk assessment of the active substance. In addition, pursuant to point 10 of Annex VI to Regulation (EU) No 528/2012, the product assessment shall include an evaluation as to whether the conditions of Article 5(2) of Regulation (EU) No 528/2012 can be satisfied. 2) Products shall only be authorised for use in Member States where at least one of the conditions laid down in Article 5(2) of Regulation (EU) No 528/2012 is met. 3) In view of the risks identified for the uses assessed, the product assessment shall pay particular attention to surface water, sediment, soil and groundwater for products used in paints which are intended to be used outdoors. The placing on the market of treated articles is subject to the condition that the person responsible for the placing on the market of a treated article treated with or incorporating carbendazim shall ensure that the label of that treated article provides the information listed in the second subparagraph of Article 58(3) of Regulation (EU) No 528/2012.